Charles Moore,  —

Charles is a force to be reckoned with in the world of print and new media. From an interview with him in LowEndMac: ”His articles, features, and commentaries have appeared in more than 40 magazines, newspapers and websites in Canada, the US, the UK, and Australia. . . a columnist for The Halifax Daily News and the Saint John Telegraph Journal, Atlantic Fisherman, and news editor and columnist for Applelinks.com, a columnist and contributing editor for MacOpinion and PBCentral, as well as writing for Low End Mac.” Charles serves as the Senior Section Editor for the Science and Research section of BioNews Texas and contributes science-related articles on a daily basis.

Articles by Charles Moore

Sarepta Therapeutics To Submit Rolling New Drug Application For Duchenne Muscular Dystrophy Treatment Eteplirsen

Sarepta Therapeutics, Inc. , a biopharmaceutical company focused on developing innovative RNA-based therapeutics, has announced a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) pertaining to its lead product candidate eteplirsen — a Duchenne muscular dystrophy (DMD) treatment. Sarepta and the agency are agreed…

Video Game Technology Could Expand Clinical Trials Eligibility For Persons With Duchenne Muscular Dystrophy

Researchers at Nationwide Children’s Hospital in Columbus, Ohio have developed a method for measurement of upper extremity movement in muscular dystrophy patients that employs interactive video game technology. The objective is an expansion of inclusion criteria for patients using wheelchairs who participate in clinical trials. Duchenne muscular dystrophy,…